Qiagen Taps CMM to Help Develop Women's Health Biomarkers | GenomeWeb
NEW YORK (GenomeWeb News) – Qiagen will use a database and software, as well as clinical samples, from the Center for Molecular Medicine in research aimed at developing biomarkers for breast cancer and other women’s health issues, the company said today.
 
The agreement gives Qiagen access to CMM’s XenoBase software and database, which was developed by CMM’s partner, the Van Andel Research Institute, to “identify clinically actionable associations between diseases, biomarkers and treatments,” the company said. 
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.